These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27446500)

  • 1. RGD Peptide Cell-Surface Display Enhances the Targeting and Therapeutic Efficacy of Attenuated Salmonella-mediated Cancer Therapy.
    Park SH; Zheng JH; Nguyen VH; Jiang SN; Kim DY; Szardenings M; Min JH; Hong Y; Choy HE; Min JJ
    Theranostics; 2016; 6(10):1672-82. PubMed ID: 27446500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attenuated Salmonella Typhimurium with truncated LPS and outer membrane-displayed RGD peptide for cancer therapy.
    Liang K; Tian Z; Chen X; Li M; Zhang X; Bian X; Ali MK; Kong Q
    Biomed Pharmacother; 2022 Nov; 155():113682. PubMed ID: 36095964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells.
    Shan D; Li J; Cai P; Prasad P; Liu F; Rauth AM; Wu XY
    Drug Deliv Transl Res; 2015 Feb; 5(1):15-26. PubMed ID: 25787336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designed synthetic analogs of the α-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin αvβ3 homing domain.
    Diao Y; Han W; Zhao H; Zhu S; Liu X; Feng X; Gu J; Yao C; Liu S; Sun C; Pan F
    J Pept Sci; 2012 Jul; 18(7):476-86. PubMed ID: 22641352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RGD binding to integrin alphavbeta3 affects cell motility and adhesion in primary human breast cancer cultures.
    Georgoulis A; Havaki S; Drosos Y; Goutas N; Vlachodimitropoulos D; Aleporou-Marinou V; Kittas C; Marinos E; Kouloukoussa M
    Ultrastruct Pathol; 2012 Dec; 36(6):387-99. PubMed ID: 23181508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward the development of a novel non-RGD cyclic peptide drug conjugate for treatment of human metastatic melanoma.
    Redko B; Tuchinsky H; Segal T; Tobi D; Luboshits G; Ashur-Fabian O; Pinhasov A; Gerlitz G; Gellerman G
    Oncotarget; 2017 Jan; 8(1):757-768. PubMed ID: 27768593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RGD peptide-modified multifunctional dendrimer platform for drug encapsulation and targeted inhibition of cancer cells.
    He X; Alves CS; Oliveira N; Rodrigues J; Zhu J; Bányai I; Tomás H; Shi X
    Colloids Surf B Biointerfaces; 2015 Jan; 125():82-9. PubMed ID: 25437067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene.
    Xiong Z; Cheng Z; Zhang X; Patel M; Wu JC; Gambhir SS; Chen X
    J Nucl Med; 2006 Jan; 47(1):130-9. PubMed ID: 16391197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and functional evaluation of RGD-modified streptavidin targeting to integrin-expressing melanoma cells.
    Syrkina MS; Shirokov DA; Rubtsov MA; Kadyrova EL; Veiko VP; Manuvera VA
    Protein Eng Des Sel; 2013 Feb; 26(2):143-50. PubMed ID: 23161915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
    Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
    Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RGD mimetics γ-AApeptides and methods of use (US 20,140,004,039 A1): a patent evaluation.
    Wu H; Jiang J; Xu H; Li Q; Cai J
    Expert Opin Ther Pat; 2016; 26(1):131-7. PubMed ID: 26560186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression, purification, and characterization of RGD-mda-7, a His-tagged mda-7/IL-24 mutant protein.
    Liu JJ; Zhang BF; Yin XX; Pei DS; Yang ZX; Di JH; Chen FF; Li HZ; Xu W; Wu YP; Zheng JN
    J Immunoassay Immunochem; 2012; 33(4):352-68. PubMed ID: 22963485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature.
    Temming K; Schiffelers RM; Molema G; Kok RJ
    Drug Resist Updat; 2005 Dec; 8(6):381-402. PubMed ID: 16309948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RGD-expressed bacterial membrane-derived nanovesicles enhance cancer therapy
    Gao J; Wang S; Dong X; Wang Z
    Theranostics; 2021; 11(7):3301-3316. PubMed ID: 33537088
    [No Abstract]   [Full Text] [Related]  

  • 15. A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma.
    Shi K; Li J; Cao Z; Yang P; Qiu Y; Yang B; Wang Y; Long Y; Liu Y; Zhang Q; Qian J; Zhang Z; Gao H; He Q
    J Control Release; 2015 Nov; 217():138-50. PubMed ID: 26368312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RGD-IL-24, a novel tumor-targeted fusion cytokine: expression, purification and functional evaluation.
    Xiao B; Li W; Yang J; Guo G; Mao XH; Zou QM
    Mol Biotechnol; 2009 Feb; 41(2):138-44. PubMed ID: 18953678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent antitumor effect elicited by RGD-mda-7, an mda-7/IL-24 mutant, via targeting the integrin receptor of tumor cells.
    Zhang BF; Liu JJ; Pei DS; Yang ZX; Di JH; Chen FF; Li HZ; Xu W; Wu YP; Zheng JN
    Cancer Biother Radiopharm; 2011 Oct; 26(5):647-55. PubMed ID: 21902545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering.
    Guo Z; He B; Jin H; Zhang H; Dai W; Zhang L; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
    Biomaterials; 2014 Jul; 35(23):6106-17. PubMed ID: 24794924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
    Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
    Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.